



SAC PHARMA PARTNERS INC.

CORPORATE PRESENTATION | JULY 2019

PRIVATE & CONFIDENTIAL

The information contained herein is not intended to be a source of investment advice on Sac Pharma Partners Inc. or the material presented.

DISCLAIMER


This document contains a presentation of Sac Pharma Partners Inc. (referred to as "Sac Pharma", or "Company"). The information contained in this document has not been independently verified and is subject to change including material updating, revision and amendment. No representation or warranty, express or implied, is made or given by or on behalf of Sac Pharma or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. The communication of this presentation in or to persons in certain jurisdictions may be restricted by law and persons who may receive communication of this presentation should inform themselves about, and observe, any such restrictions in advance of communication to them of this presentation. No securities exchange or affiliated service provider has reviewed or accepts responsibility for the adequacy or accuracy of the content of this presentation. The material contained in this presentation is provided solely for your general knowledge and is not intended to be a comprehensive review of all matters and developments concerning Sac Pharma. The Company has taken all reasonable care in producing the information contained in this presentation. This information may contain technical or other inaccuracies, omissions, or typographical errors, for which Sac Pharma assumes no responsibility and makes no representation or warranty regarding, and assumes no responsibility for, the use, validity, accuracy, completeness, reliability or currency of any claims, statements or information in this presentation. To the extent permitted by law, Sac Pharma and its employees, agents, affiliates and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission. Statements in this presentation including statements relating to Sac Pharma's future plans, objectives or expected results, constitute forward- looking statements within the meaning of the U.S. federal and Canadian securities laws. Forward-looking statements are based on numerous assumptions and are subject to the risks and uncertainties inherent in its business, including risks inherent in early stage companies. As a result, actual results may vary materially from those described in the forward- looking statements. Sac Pharma disclaims any obligation to update any forward-looking statements. This presentation was prepared to assist interested parties in making their own assessment of the Company and its business plans and does not purport to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company, its assets and the information provided in this presentation. Any and all statements, forecasts, projections and estimates contained in this presentation are based on management's current knowledge and no representation or warranty is made as to their accuracy and/or reliability. Information contained in this presentation is the property of Sac Pharma.

OVERVIEW

- ❖ The project at 1300 El Monte takes advantage of the favorable regulatory environment present in Sacramento, CA.
- ❖ This project takes advantage of a variety of key factors including: (1) favourable geographic location, (2) favourable regulatory landscape, (3) Executive team's existing footprint within the industry, (4) a robust and well developed commercial cannabis marketplace, and (5) some of the lowest electricity rates (SMUD) in the State.
- ❖ This project is an "A+" location with proximity to all major freeway interchanges, sitting adjacent I-5, Highway 50, I-80, the 160 corridor to Downtown Sacramento. It is a fully enclosed building with a secure attached yard.
- ❖ Sacramento is one of the most densely populated cannabis jurisdictions with the highest number of permitted dispensaries per capita than any other jurisdiction in the State. The city has a thriving retail and wholesale market, and is in a unique position to service both the wholesale and retail segments of the industry.

CANNABIS IN CALIFORNIA

- ❖ As of January 1st, 2018, California approved sales in medicinal and recreational cannabis throughout the state.
- ❖ All producers and resellers of cannabis products must be compliant with the Medical Marijuana Regulation and Safety Act (“MMRSA”) legislation as prescribed by the State of California.
- ❖ Non-MMRSA compliant producers and resellers are being served with cease and desist notifications.



**of the legal market
accounted by USA, with
California contributing half
of that.**

*Report: Canada and
International Cannabis Markets
– Brightfield Group 2018

**GLOBAL LEGAL CANNABIS MARKET
IS \$7.7BN; EXPECTED TO RISE 60%
TO \$31.4BN BY 2021 ***



WHY SACRAMENTO?

- ❖ Sacramento represents some of the best regulatory policies and procedures for streamlining operations and delivering products to market. That said, the demand for projects within the City's limits is so strong, that the pool of available development projects is quickly shrinking.
- ❖ The City and State have worked closely together to ensure there is a consistent and reliable framework under which investors are comfortable participating. The result has been a pro-business approach that supports local enterprise while providing robust systems and controls to ensure transparency and public safety.

INTRODUCING OUR 15,000 SQ.FT. CULTIVATION FACILITY

SACRAMENTO, CA



SACRAMENTO FACILITY

The Sacramento Facility is situated on 0.51 acres and received a conditional use permit for cannabis cultivation from the City of Sacramento on January 24, 2018. Sac Pharma also received a state license from the CFDA on January 1, 2018 to flower 10,000 SF of canopy within the Sacramento Facility. The facility is an existing 15,000 square feet warehouse with a fully enclosed secure yard with on-site parking.


Once expansion of the Sacramento Facility is complete, Sac expects to generate four harvests in the first year of operations – 2019 – subsequently growing to five harvests by 2021.



**THE FACILITY COMMENCED FULL-SCALE
COMMERCIAL PRODUCTION IN MARCH
OF 2019.**



FACILITY RETROFIT TIMELINE





STEADY STATE OPERATIONS

Sac Pharma takes the guesswork out of running a cultivation facility. With proprietary recipes and formulas, high demand strains, and key distributor relationships, the well established team at Sac Pharma not only grows a product that looks and smells good, but sells just as well. Consistently outperforming its peers, Sac Pharma offers high end bulk product that is sold before each harvest.

Sac Pharma will optimize revenue by ensuring each harvest contains the maximum Grade A flower, and all parts of the plants are sold, leaving virtually no waste. By pre-selling harvests, the company can stay ahead of changing tastes and preferences, while coordinating off-take agreements with its distribution partners.

SHORT TERM COMPANY OBJECTIVES



MANAGEMENT & BOARD OF DIRECTORS

Corey Travis

President & Chief Executive Officer

Holding a Bachelor of Science degree in Business Administration, Mr. Travis has been involved in the regulated cannabis industry since 2011. He has served as an advisor to several local jurisdictions in California to foster and govern the evolving cannabis industry. Mr. Travis is the founder of CannaLicensed, a cannabis business consulting firm that has helped clients to complete and submit cannabis license applications and to design efficient and effective cannabis facilities.

Mr. Travis excels in navigating the political and regulatory processes in the legal California cannabis market. He has a proven operations track record in California across retail, wholesale, production and related compliance over the past seven years. During that time, he has secured public support, land use entitlements and operating permits for a variety of permitted verticals.

Mr. Travis has been an executive of several California cannabis retailers and wholesalers as well as a founder of the successful Tahoe Hydroponics Company in Nevada.

MANAGEMENT & BOARD OF DIRECTORS

Zula Kropivnitski

Chief Financial Officer

Ms. Kropivnitski has been the Chief Financial Officer and Secretary of the Company since October 11, 2012 and a director of the Company since October 21, 2015. Ms. Kropivnitski has served as the Chief Financial Officer and director for various public companies and has been instrumental in their growth. Her role as Chief Financial Officer include Lexagene Holdings Inc, Healthspace, Abraplata Resource and Shelby Ventures Inc. Ms. Kropivnitski had also been a director at Rockshield Capital Corp from November 2016 to November 2017. Ms. Kropivnitski continues to serve as a Controller of Preakness Management Ltd., a private company. Ms. Kropivnitski has over ten years of international experience in the resource sector. Ms. Kropivnitski served as the Controller to Sacre-Coeur Minerals and African Queen Mines Ltd., and served as Senior Accountant to Manex Resource Group and its group of mining exploration companies. During her tenure, she was responsible for all areas of financial reporting, corporate finance and regulatory compliance. Ms. Kropivnitski received her Certified General Accountant professional accounting designation from the Certified General Accountants Association of British Columbia, Canada and later obtained her ACCA designation from the Association of Chartered Certified Accountants. She also has Master of Mathematics and Master of Economics.

MANAGEMENT & BOARD OF DIRECTORS

Christopher Cooper, MBA

Director

Mr. Cooper has been a director of the Company since January 26, 2016. Mr. Cooper has extensive experience in senior management of both public and private companies. He has founded several resource companies internationally, as well as, domestically. Mr. Cooper received his Bachelor of Business Administration from Hofstra University in Hempstead, NY and his Masters of Business Administration from Dowling College in Oakdale, NY.

Charanjit Hayre

Director

Mr. Charanjit Hayre is Chief Operating Officer & Director at Taipak Enterprises Ltd. and Chief Operating Officer & Director at Easysnap NA. He is on the Board of Directors at Taipak Enterprises Ltd., Easysnap NA, and Spriza Media, Inc. Mr. Hayre was previously employed as Independent Director by Iron Tank Resources Corp., Executive Vice President by Great Bear Resources Ltd., Chief Operating Officer by Asentus Consulting Group Ltd., and Senior Manager-Enterprise Risk Services Group by Deloitte & Touche LLP. He also served on the board at MAX Minerals Ltd.

STRONG INDUSTRY RELATIONSHIPS

- ❖ Sac Pharma participates in exclusive premium branding events in California such as High Times, along with other key media partners, which bring the company maximum reach and impressions.
- ❖ High Times is the global hub for cannabis related information.
- ❖ High Times anticipates listing on NASDAQ in 2018 and will be a permanent media and events partner with Sac Pharma.

KEY DISPENSARY RELATIONSHIPS



COMPARABLE COMPANIES



Symbol: **PLTH**

Stock Price: **\$2.44**

Market Cap: **\$190M**



Symbol: **NGW**

Stock Price: **\$0.43**

Market Cap: **\$52M**



Symbol: **MMEN**

Stock Price: **\$4.16**

Market Cap: **\$126M**



HERITAGE **CANNABIS**
Holdings Corp

Symbol: **CANN**

Stock Price: **\$0.135**

Market Cap: **\$63M**

CONTACT US



SAC PHARMA PARTNERS INC.

Please do not hesitate to contact us with any questions, comments or general inquires.

COREY TRAVIS, PRESIDENT & CEO

Email

coreyrtravis@gmail.com